Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
Hanna CR, O'Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, Devlin L, Edwards J, Gaya DR, Kelly CA, Lewsley LA, Maka N, Morrison P, Dinnett L, Dillon S, Gourlay J, Platt JJ, Thomson F, Adams RA, Roxburgh CSD. Hanna CR, et al. Among authors: adams ra. Radiat Oncol. 2021 Dec 2;16(1):230. doi: 10.1186/s13014-021-01941-z. Radiat Oncol. 2021. PMID: 34857017 Free PMC article. No abstract available.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Maughan TS, et al. Among authors: adams ra. Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5. Lancet. 2011. PMID: 21641636 Free PMC article. Clinical Trial.
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T; FOCUS4 Trial Investigators. Adams R, et al. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):162-171. doi: 10.1016/S2468-1253(17)30394-1. Epub 2017 Dec 16. Lancet Gastroenterol Hepatol. 2018. PMID: 29254887 Free PMC article. Clinical Trial.
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM, Adams R, Downing A, Glynne-Jones R, Harrison M, Hawkins M, Sebag-Montefiore D, Gilbert DC, Muirhead R. Jones CM, et al. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1202-1211. doi: 10.1016/j.ijrobp.2018.04.033. Epub 2018 Apr 19. Int J Radiat Oncol Biol Phys. 2018. PMID: 29859793 Free article.
A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).
O'Cathail SM, Davis S, Holmes J, Brown R, Fisher K, Seymour L, Adams R, Good J, Sebag-Montefiore D, Maughan T, Hawkins MA. O'Cathail SM, et al. Radiat Oncol. 2020 Jun 12;15(1):151. doi: 10.1186/s13014-020-01593-5. Radiat Oncol. 2020. PMID: 32532291 Free PMC article. Clinical Trial.
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
Hanna CR, O'Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, Devlin L, Edwards J, Gaya DR, Kelly CA, Lewsley LA, Maka N, Morrison P, Dinnett L, Dillon S, Gourlay J, Platt JJ, Thomson F, Adams RA, Roxburgh CSD. Hanna CR, et al. Among authors: adams ra. Radiat Oncol. 2021 Aug 26;16(1):163. doi: 10.1186/s13014-021-01888-1. Radiat Oncol. 2021. PMID: 34446053 Free PMC article.
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Adams RA, Fisher DJ, Graham J, Seligmann JF, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, Butler R, Brown E, Collinson F, Falk S, Wasan H, Shiu KK, Middleton G, Samuel L, Wilson RH, Brown LC, Maughan TS; FOCUS4 Trial Investigators. Adams RA, et al. J Clin Oncol. 2021 Nov 20;39(33):3693-3704. doi: 10.1200/JCO.21.01436. Epub 2021 Sep 13. J Clin Oncol. 2021. PMID: 34516759 Free PMC article. Clinical Trial.
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.
Brown LC, Graham J, Fisher D, Adams R, Seligmann J, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, Butler R, Shiu K, Middleton G, Samuel L, Wilson RH, Maughan TS; FOCUS4 Trial Investigators. Brown LC, et al. Clin Trials. 2022 Apr;19(2):146-157. doi: 10.1177/17407745211069879. Epub 2022 Jan 27. Clin Trials. 2022. PMID: 35083924 Free PMC article. Clinical Trial.
242 results